

Update on diagnosis and treatment of NMOSD and MOGAD

WEDNESDAY, 21 JANUARY 2026

08.45	Welcome & Introduction
09.00 - 11.00	Session 1: Clinical and MRI features of NMOSD and MOGAD
09.00	NMOSD: Epidemiology, clinical and MRI features
09.30	MOGAD: Epidemiology, clinical and MRI features
10.00	Specific features in paediatric onset NMOSD and MOGAD
10.30	Late onset NMOSD and MOGAD (including comorbidities)
11.00 - 11.30	Coffee Break
11.30 - 13.00	Session 2: Pathology and etiopathogenesis
11.30	The pathology of NMOSD and MOGAD
12.00	Etiopathogenesis / Immunology of NMOSD and MOGAD
12.30	Antibody assays
13.00 - 14.00	Lunch Break

14.00 - 17.00	Session 3: Diagnosis and use of other paraclinical testing
14.00 - 15.00	Lecture: Diagnostic criteria of NMOSD, MOGAD and seronegative
14.00 - 14.30	Part 1
14.30 - 15.00	Part 2
15.00 - 15.30	Coffee Break
15.30 - 17.00	Session 3 continuing: Diagnosis and use of other paraclinical testing
15.30	Conventional MRI
16.00	OCT and VEP
16.30	Body fluid biomarkers
17.00	End of Day 1

THURSDAY, 22 JANUARY 2026

09.00 - 11.00 Session 4: Treatment, monitoring and evidence on predictive factors

09.00 Acute management of NMOSD and MOGAD

09.30 Preventative immunotherapy in AQP4+ NMOSD

10.00 Preventative immunotherapy in MOGAD

10.30 Symptomatic treatment in NMOSD and MOGAD

11.00 - 11.30 Coffee Break

11.30 - 13.00 Session 5: Monitoring and predictive factors

11.30 How to predict relapses and disability outcomes in NMOSD and MOGAD

12.00 Tools for monitoring in clinical practice (MRI, OCT, body fluid biomarkers)

12.30 Impact of pregnancy and breastfeeding in management

13.00 - 14.00 Lunch Break

14.00 - 17.30	Workshop 1 and 2 (two groups, participants will rotate workshops) Workshop 1: How to diagnose NMOSD and MOGAD (Consider mimicks) Workshop 2: When to start and stop preventative immunotherapy
15.30 - 16.00	Coffee Break
16.00 - 17.30	Workshop 1 and 2 (two groups, participants will rotate workshops)
17.30	End of Day 2

FRIDAY, 23 JANUARY 2026

08.45 - 10.30

Working Groups A-C

Participants will work in 3 groups and will prepare projects for clinical practice and / or research that include algorithm proposals to make the differential diagnosis of NMOSD and MOGAD, and about the role of paraclinical testing and other data as prognostic factors. Participants will receive feedback from senior investigators.

Working Group A: Clinical cases illustrating usefulness and limitations of the diagnostic criteria of NMOSD and MOGAD (include seronegative case)

Working Group B: MRI for differential diagnosis and prognosis

Working Group C: Body fluid biomarkers in diagnosis and prognosis (include seronegative case)

10.30 - 11.00

Coffee Break

11.00 - 12.00

Participants' presentations by coordinators of the Working Group, 20 minutes per group

12.00 - 13.00

Plenary session

12.00

The future: Gaps in knowledge and challenges (imaging, body fluid biomarkers, treatment: CAR-T, transplantation, tolerization strategies)

12.40 - 13.00

Discussion

13.00 - 13.15

Wrap-up & Adjournment

13.15

Lunch and individual departure